The inaugural CHINATRIALS+US Summit launches in the midst of the recent boom of new innovative Chinese biotech startups coupled with recent CFDA reforms that enable multinational biopharma to more easily import their foreign-approved drugs to China.
CHINATRIALS+US brings together 100+ senior clinical development executives from Chinese innovative biotechs interested in conducting clinical trials in the US and US biotechs who have interest conducting clinical trials in or entering the China market.
The focus of discussion will be on the strategic and technical considerations these companies should consider when entering the US or China markets. We hope the synergies of bringing these two important groups together will introduce new opportunities for partnerships and collaborations for parallel drug development in the US and China.
Now in its 12th year, the annual CHINATRIALS Summit has established itself as the must-attend industry-focused event for global clinical development executives interested in China development.
CHINATRIALS brings together 400+ senior clinical development executives from multinational biopharmaceutical companies and domestic pharmaceutical and new start-up biotechs.
The Summit covers a wide range of important topics for the Chinese market including regulatory policy, clinical strategy development, clinical trial design, registering imported drugs, and more. It is the only event you need to attend this year to stay updated on the scientific AND business-sides of China’s fast-moving clinical development industry.